hereafter. All the cost for the manufacturing/purchase of anti-IgE Product and all the cost for its marketing and sale in the US including all supporting and auxiliary activities and royalties to third parties (if any) shall be shared between Ciba and Genentech on a * basis. All the net profits from the commercialization of the anti-IgE Product in the US shall be shared between Ciba and Genentech on a * basis.
Appears in 3 contracts
Sources: Settlement and Cross Licensing Agreement (Tanox Inc), Settlement & Cross Licensing Agreement (Tanox Inc), Settlement and Cross Licensing Agreement (Tanox Inc)